Blog
RSS FeedPosted by Michael Wonder on 26 Oct 2021
NICE draft guidance does not recommend tucatinib for advanced breast cancer
26 October 2021 - NICE has today published draft guidance for public consultation which does not recommend tucatinib (Tukysa; Seagen), in ...
Posted by Michael Wonder on 21 Oct 2021
NICE recommends gene silencing therapy for porphyria patients on NHS
21 October 2021 - NICE have recommended the use of givosiran, a gene silencing therapy, on the NHS in England, as ...
Posted by Michael Wonder on 18 Oct 2021
NICE approves Ofev for PF-ILD
18 October 2021 - NICE has recommended Boehringer Ingelheim’s Ofev (nintedanib) for the treatment of adult patients with chronic fibrosing ...
Posted by Michael Wonder on 18 Oct 2021
New asthma drug approved on NHS branded a ‘wonder drug’
18 October 2021 - NICE has issued a Final Appraisal Determination recommending dupilumab as an add-on maintenance treatment for severe ...
Posted by Michael Wonder on 15 Oct 2021
NICE clears Opdivo for resected oesophageal or gastro-oesophageal junction cancer
15 October 2021 - The UK NICE has recommended BMS' Opdivo (nivolumab) as a treatment option for certain resected oesophageal ...
Posted by Michael Wonder on 11 Oct 2021
Consternation as NICE rejects Janssen MS drug Ponvory
8 October 2021 - NICE has delivered its first verdict on NHS funding of Janssen’s oral multiple sclerosis drug Ponvory, ...
Posted by Michael Wonder on 06 Oct 2021
NICE terminates another appraisal for a Roche medicine
6 October 2021 - The sixth termination of the appraisal of a Roche medicine. ...
Posted by Michael Wonder on 05 Oct 2021
Venetoclax comes close to gaining support from NICE
4 October 2021 - A proposal from AbbVie for a Cancer Drugs Fund listing may get it over the line. ...
Posted by Michael Wonder on 05 Oct 2021
NICE recommends first treatment in two decades for sickle cell disease
5 October 2021 - Hundreds of people will be eligible for a new treatment for sickle cell disease following draft guidance ...
Posted by Michael Wonder on 30 Sep 2021
People with advanced or metastatic urothelial cancer to get life-extending treatment
30 September 2021 - Around 130 people per year with untreated locally advanced or metastatic urothelial cancer will be eligible for ...
Posted by Michael Wonder on 16 Sep 2021
BioCryst’s HAE med Orladeyo wins NICE nod
16 September 2021 - BioCryst’s Orladeyo (berotralstat) has received a positive recommendation from NICE for preventing recurrent attacks of hereditary ...
Posted by Michael Wonder on 15 Sep 2021
NICE backs Opdivo for head and neck cancer
15 September 2021 - NICE has recommended Bristol Myers Squibb’s (BMS) immunotherapy Opdivo (nivolumab) for routine use on the NHS ...
Posted by Michael Wonder on 12 Sep 2021
NHS lung cancer patients in England get early access to ‘breakthrough’ cancer drug
10 September 2021 - The MHRA has approved a first-of-its-kind cancer drug – capable of targeting a gene mutation that ...
Posted by Michael Wonder on 09 Sep 2021
NICE recommends treatment for people with juvenile idiopathic arthritis
9 September 2021 - NICE has today published final draft guidance which recommends tofacitinib (Xeljanz; Pfizer) as an option for treating ...
Posted by Michael Wonder on 08 Sep 2021
Nivolumab scores a rare 'no' from NICE
8 September 2021 - Nivolumab scores only its second final rejection to date from NICE. ...